Approved for adults with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and (if RAS wild-type) anti-EGFR therapy; also approved for metastatic gastric/GE junction adenocarcinoma after two or more prior chemotherapy regimens.